Novel Method for Selecting Immunosuppressive Histone Deacetylase (HDAC) Inhibitors with Minimal Thrombocytopenia

Histone deacetylase (HDAC) inhibitors repress interleukin-2 (IL-2) gene expression in T cells and possess immunosuppressive activity in vivo. In addition to its immunosuppressive activity, HDAC inhibitors block GATA binding protein-1 (GATA-1) gene expression in megakaryocytes and elicit thrombocytop...

Full description

Saved in:
Bibliographic Details
Published inBiological & pharmaceutical bulletin Vol. 31; no. 2; pp. 305 - 308
Main Authors Matsuoka, Hideaki, Fujimura, Takao, Unami, Akira, Yamada, Toshiko, Noto, Takahisa, Takata, Yoko, Yoshizawa, Katsuhiko, Mori, Hiroaki, Aramori, Ichiro, Mutoh, Seitaro
Format Journal Article
LanguageEnglish
Published Japan The Pharmaceutical Society of Japan 01.02.2008
Japan Science and Technology Agency
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Histone deacetylase (HDAC) inhibitors repress interleukin-2 (IL-2) gene expression in T cells and possess immunosuppressive activity in vivo. In addition to its immunosuppressive activity, HDAC inhibitors block GATA binding protein-1 (GATA-1) gene expression in megakaryocytes and elicit thrombocytopenia. In this report we state that for a given immunosuppressive dose of HDAC inhibitor, the ratio of GATA-1 reporter gene activity relative to IL-2 reporter gene assay (G/I ratio of measured IC50) can be predictive of a HDAC inhibitor's thrombocytopenic effect. This study utilized nine HDAC inhibitors at a minimal effective dose in a rat heterotopic cardiac transplantation model and the resultant G/I ratios and platelet depletion rates were highly correlated (r=0.933). These results indicate that calculation of G/I ratio can be a novel method for selecting immunosuppressive HDAC inhibitor having minimal thrombocytopenic effect which will benefit the search for new immunosuppressants of greater safety and efficacy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0918-6158
1347-5215
DOI:10.1248/bpb.31.305